D.A. Davidson raises Customers Bancorp stock price target on growth By Investing.com

D.A. Davidson raised its price target on Customers Bancorp to $93 from $91 and reaffirmed a Buy rating, citing a solid quarter, strong loan and deposit growth, and maintained 2026 outlook. The bank is also pushing ahead with AI integration via a multiyear OpenAI collaboration, targeting an efficiency ratio improvement from about 49% to the low 40s by 2027. Additional governance updates include a new supplemental retirement plan for CEO Samvir Sidhu and director Robert Mackay's planned retirement after the 2026 annual meeting.

Analysis

The real signal here is not the target raise; it is that the market is still underpricing the optionality embedded in CUBI’s deposit franchise transformation. If the bank can keep adding relationship bankers without a meaningful step-up in funding costs, earnings power should re-rate faster than the current multiple implies because deposit mix improvement tends to show up with a lag and then compounds through lower beta and better loan growth capacity. That creates a second-order benefit: a stronger deposit base should also reduce the need to chase wholesale funding, which can widen the spread between reported growth and normalized earnings quality.

The OpenAI partnership is more than a branding event. If management actually drives the efficiency ratio into the low 40s, that is a multi-hundred-basis-point operating leverage story that can justify a materially higher terminal multiple, especially for a sub-scale bank that is trying to close the gap with larger peers on cost structure. The market usually discounts AI initiatives at banks as slideware, but the embedded-engineer model suggests process redesign rather than superficial chatbots, which is the only version that can move the needle on expense run-rate over 12-24 months.

The main risk is that credit remains benign just long enough for investors to extrapolate too aggressively, while private credit contagion and pockets of consumer stress show up later in the cycle. For a bank like this, the danger is not headline NPLs next quarter; it is a lagged deterioration in non-depository and commercial exposures that forces the market to pay closer attention to reserve build and funding discipline. Governance overhang is also minor but not zero: succession and board turnover can matter if execution slips while the valuation is already close to fair on near-term earnings.

Consensus may be missing that the setup is less about near-term upside and more about durability of the franchise rebuild. The stock can rerate on a cleaner, cheaper operating model even if absolute earnings growth moderates, but that only works if deposit momentum persists through a less forgiving rate environment. In other words, this is a quality-vs-valuation story, not a pure earnings beat trade.

Key Decisions for Investors

• Go long CUBI on pullbacks into the low-$70s, targeting a 3-6 month move toward the low-to-mid $90s if deposit growth and expense leverage remain intact; downside should be capped if the stock reverts to ~9x forward earnings, but reserve slippage could cut that thesis quickly.
• For a cleaner expression of AI-enabled operating leverage, pair long CUBI vs short a regional bank ETF basket over 6-12 months; the trade works if CUBI’s efficiency ratio inflects while the group remains stuck in slower-growth, lower-opex-downside mode.
• Buy out-of-the-money CUBI calls 3-9 months out to capture rerating optionality from the 2026 efficiency target; premium is justified because the catalyst path is longer-dated and the upside is convex if execution surprises positively.
• Trim or hedge CUBI if private credit stress broadens in bank earnings or if deposit growth slows for two consecutive quarters; that would signal the market should stop paying up for the transformation story.
• Relative value idea: long CUBI / short a higher-multiple regional with weaker deposit momentum; the spread should widen if investors reward tangible franchise-building over static balance-sheet stories.